Elevation Oncology to Current on the Piper Sandler thirty sixth Annual Healthcare Convention By Investing.com

BOSTON, Nov. 26, 2024 /PRNewswire/ — Elevation Oncology, Inc. (Nasdaq: ELEV), an revolutionary oncology firm targeted on the invention and growth of selective most cancers therapies to deal with sufferers throughout a variety of stable tumors with important unmet medical wants, at the moment introduced that Joseph J. Ferra, President and Chief Government Officer of Elevation Oncology, will take part in a hearth chat on the Piper Sandler 36^th Annual Healthcare Convention on Tuesday, December 3, 2024, at 8:30 a.m. ET.

A stay webcast and replay of the occasion will likely be obtainable on the Occasions web page of the Firm’s Investor Relations web site at https://buyers.elevationoncology.com.

About Elevation Oncology, Inc.

Elevation Oncology is an revolutionary oncology firm targeted on the invention and growth of selective most cancers therapies to deal with sufferers throughout a variety of stable tumors with important unmet medical wants. We’re leveraging our antibody-drug conjugate (ADC) experience to advance a novel pipeline, initially concentrating on two clinically validated targets in oncology, Claudin 18.2 and HER3. Our lead candidate, EO-3021, is a possible best-in-class, Claudin 18.2 ADC and is at the moment being evaluated within the dose growth portion of a Section 1 trial (NCT05980416) in sufferers with superior, unresectable or metastatic gastric/gastroesophageal adenocarcinoma that categorical Claudin 18.2. Moreover, we anticipate to appoint a growth candidate for our second program, a HER3-targeting ADC for the remedy of sufferers with stable tumors that overexpress HER3, in 2024. For extra info, go to www.ElevationOncology.com.

Elevation Oncology Investor and Media Contact

Gracie TongSenior Director, Investor Relations and Company Communications
gtong@elevationoncology.com